Key studies that have changed the history and treatment of early HER2+ breast cancer: focus on individual therapy

Key studies that have changed the history and treatment of early HER2+ breast cancer: focus on individual therapy

HER2-positive breast cancer is a unique subtype of the disease, not only in terms of aggressive biology, but also in terms of treatment options. Over the past 15 years, the strategy for treating early HER2-positive breast cancer has undergone a real evolution – from the absence of anti-HER2 therapy...

Celý popis

Podrobná bibliografie
Hlavní autoři: I. V. Kolyadina, I. V. Poddubnaya
Médium: Článek
Jazyk:Russian
Vydáno: ABV-press 2021-01-01
Edice:Опухоли женской репродуктивной системы
Témata:
early her2-positive breast cancer stage i–iii
adjuvant anti-her2 therapy
neoadjuvant therapy
t-dm1 in post neoadjuvant therapy
predictors of anti-her2 therapy efficacy
pcr
escalation and de-escalation of treatment
On-line přístup:https://ojrs.abvpress.ru/ojrs/article/view/766

Internet

https://ojrs.abvpress.ru/ojrs/article/view/766

Podobné jednotky